Intended for healthcare professionals


Biological treatment is approved for severe eosinophilic asthma

BMJ 2016; 355 doi: (Published 01 December 2016) Cite this as: BMJ 2016;355:i6472
  1. Susan Mayor
  1. London

Draft guidance from the National Institute for Health and Care Excellence (NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels.1

The decision follows an agreement by the manufacturer, GlaxoSmithKline (GSK), to reduce the price of the drug—which has a list price of £840 (€992; $1046) for a once monthly dose—to a lower, but undisclosed, cost to the NHS.

Mepolizumab is a humanised monoclonal antibody that binds to interleukin …

View Full Text

Log in

Log in through your institution


* For online subscription